CD274 and ovarian cancer: AZD5153, a novel BRD4 inhibitor, showed M2 macrophage repolarization and activation of CD8 + T lymphocytes in addition to sensitizing ovarian cancer cell lines to anti-PD-L1 antibodies [167].